{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:17Z","timestamp":1786982837727,"version":"build-2736575974"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R25DA054015"],"award-info":[{"award-number":["R25DA054015"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R34DA058162"],"award-info":[{"award-number":["R34DA058162"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US DHHS Office of Minority Health","award":["CPIMP221346"],"award-info":[{"award-number":["CPIMP221346"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Racial and Ethnic Health Disparities"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40615-024-02142-6","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T11:02:06Z","timestamp":1724842926000},"page":"3375-3387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Associations Between Opioid and Kratom Use in the USA: Differences by Race\/Ethnicity and Sexual Orientation"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-4179","authenticated-orcid":false,"given":"Cassidy R.","family":"LoParco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlton","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla J.","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Rossheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah C.","family":"Peeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla K.","family":"Tillett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Chul","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"issue":"1","key":"2142_CR1","first-page":"26032","volume":"23","author":"K Shah","year":"2021","unstructured":"Shah K, Tankersley W, Mekala H. Kratom: an emerging issue and need for regulations in the United States. Prim Care Companion CNS Disord. 2021;23(1):26032.","journal-title":"Prim Care Companion CNS Disord"},{"key":"2142_CR2","unstructured":"National Archives Federal Register. Withdrawal of notice of intent to temporarily place mitragynine and 7-hydroxymitragynine into schedule I 2016 [Available from: https:\/\/www.federalregister.gov\/documents\/2016\/10\/13\/2016-24659\/withdrawal-of-notice-of-intent-to-temporarily-place-mitragynine-and-7-hydroxymitragynine-into. Accessed\u00a0Oct 2023."},{"key":"2142_CR3","first-page":"3579","volume":"2022","author":"JE Henningfield","year":"2021","unstructured":"Henningfield JE, Wang DW, Huestis MA. Kratom abuse potential 2021: an updated eight factor analysis. Front Pharmacol. 2021;2022:3579.","journal-title":"Front Pharmacol"},{"key":"2142_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.drugpo.2019.05.003","volume":"70","author":"WC Prozialeck","year":"2019","unstructured":"Prozialeck WC, Avery BA, Boyer EW, et al. Kratom policy: the challenge of balancing therapeutic potential with public safety. Int J Drug Policy. 2019;70:70\u20137.","journal-title":"Int J Drug Policy"},{"issue":"11","key":"2142_CR5","first-page":"32","volume":"33","author":"HR Tavakoli","year":"2016","unstructured":"Tavakoli HR, Buchholz AC, Kabir IK, et al. Kratom: a new product in an expanding substance abuse market. Fed Pract. 2016;33(11):32.","journal-title":"Fed Pract"},{"key":"2142_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drugalcdep.2017.03.007","volume":"176","author":"O Grundmann","year":"2017","unstructured":"Grundmann O. Patterns of kratom use and health impact in the US\u2014results from an online survey. Drug Alcohol Depend. 2017;176:63\u201370.","journal-title":"Drug Alcohol Depend"},{"key":"2142_CR7","unstructured":"NSDUH. Results from the 2021 National Survey on Drug Use and Health: Detailed Tables 2022 [Available from: \nhttps:\/\/www.samhsa.gov\/data\/sites\/default\/files\/reports\/rpt39441\/NSDUHDetailedTabs2021\/NSDUHDetailedTabs2021\/NSDUHDetailedTabsTOC2021.htm#toc.\u00a0Accessed Oct 2023."},{"issue":"12","key":"2142_CR8","first-page":"792","volume":"112","author":"WC Prozialeck","year":"2012","unstructured":"Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792\u20139.","journal-title":"J Am Osteopath Assoc"},{"key":"2142_CR9","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.3389\/fphar.2021.789075","volume":"12","author":"JM Rogers","year":"2021","unstructured":"Rogers JM, Smith KE, Strickland JC, et al. Kratom use in the US: both a regional phenomenon and a white middle-class phenomenon? Evidence from NSDUH 2019 and an online convenience sample. Front Pharmacol. 2021;12:3551.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2142_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40122-020-00151-x","volume":"9","author":"SC Eastlack","year":"2020","unstructured":"Eastlack SC, Cornett EM, Kaye AD. Kratom\u2014Pharmacology, clinical implications, and outlook: a comprehensive review. Pain Ther. 2020;9(1):55\u201369.","journal-title":"Pain Ther"},{"issue":"6","key":"2142_CR11","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/j.1360-0443.2008.02209.x","volume":"103","author":"EW Boyer","year":"2008","unstructured":"Boyer EW, Babu KM, Adkins JE, et al. Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103(6):1048\u201350.","journal-title":"Addiction"},{"key":"2142_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jep.2017.03.020","volume":"202","author":"PN Brown","year":"2017","unstructured":"Brown PN, Lund JA, Murch SJ. A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: implications for products sold as kratom. J Ethnopharmacol. 2017;202:302\u201325.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"2142_CR13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1097\/YCO.0000000000000621","volume":"33","author":"S Ramanathan","year":"2020","unstructured":"Ramanathan S, McCurdy CR. Kratom (Mitragyna speciosa): worldwide issues. Curr Opin Psychiatry. 2020;33(4):312\u20138.","journal-title":"Curr Opin Psychiatry"},{"key":"2142_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.drugalcdep.2019.05.005","volume":"202","author":"MA Coe","year":"2019","unstructured":"Coe MA, Pillitteri JL, Sembower MA, et al. Kratom as a substitute for opioids: results from an online survey. Drug Alcohol Depend. 2019;202:24\u201332.","journal-title":"Drug Alcohol Depend"},{"key":"2142_CR15","doi-asserted-by":"publisher","first-page":"107849","DOI":"10.1016\/j.drugalcdep.2020.107849","volume":"208","author":"A Garcia-Romeu","year":"2020","unstructured":"Garcia-Romeu A, Cox DJ, Smith KE, et al. Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208:107849.","journal-title":"Drug Alcohol Depend"},{"key":"2142_CR16","doi-asserted-by":"publisher","unstructured":"Henningfield JE, Chawarski MC, Garcia-Romeu A, et al. Kratom withdrawal: discussions and conclusions of a scientific expert forum. Drug Alcohol Depend Rep. 2023;7. https:\/\/doi.org\/10.1016\/j.dadr.2023.100142.","DOI":"10.1016\/j.dadr.2023.100142"},{"issue":"7","key":"2142_CR17","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1021\/acs.jnatprod.0c00257","volume":"83","author":"L Flores-Bocanegra","year":"2020","unstructured":"Flores-Bocanegra L, Raja HA, Graf TN, et al. The chemistry of kratom [Mitragyna speciosa]: updated characterization data and methods to elucidate indole and oxindole alkaloids. J Nat Prod. 2020;83(7):2165\u201377.","journal-title":"J Nat Prod"},{"issue":"3","key":"2142_CR18","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1124\/jpet.120.000189","volume":"376","author":"S Obeng","year":"2021","unstructured":"Obeng S, Wilkerson JL, Le\u00f3n F, et al. Pharmacological comparison of mitragynine and 7-hydroxymitragynine: in vitro affinity and efficacy for \u03bc-opioid receptor and opioid-like behavioral effects in rats. J Pharmacol Exp Ther. 2021;376(3):410\u201327.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2142_CR19","doi-asserted-by":"publisher","first-page":"19158","DOI":"10.1038\/s41598-020-76119-w","volume":"10","author":"DA Todd","year":"2020","unstructured":"Todd DA, Kellogg J, Wallace E, et al. Chemical composition and biological effects of kratom (Mitragyna speciosa): in vitro studies with implications for efficacy and drug interactions. Sci Rep. 2020;10(1):19158.","journal-title":"Sci Rep"},{"issue":"7","key":"2142_CR20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/toxics10070398","volume":"10","author":"W Prozialeck","year":"2022","unstructured":"Prozialeck W, Fowler A, Edwards J. Public health implications and possible sources of lead (Pb) as a contaminant of poorly regulated kratom products in the United States. Toxics. 2022;10(7):398.","journal-title":"Toxics"},{"issue":"4","key":"2142_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13181-016-0588-y","volume":"12","author":"AG Lydecker","year":"2016","unstructured":"Lydecker AG, Sharma A, McCurdy CR, et al. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. J Med Toxicol. 2016;12(4):341\u20139.","journal-title":"J Med Toxicol"},{"issue":"2","key":"2142_CR22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00213-017-4813-4","volume":"235","author":"JE Henningfield","year":"2018","unstructured":"Henningfield JE, Fant RV, Wang DW. The abuse potential of kratom according the 8 factors of the controlled substances act: implications for regulation and research. Psychopharmacology. 2018;235(2):573\u201389.","journal-title":"Psychopharmacology"},{"key":"2142_CR23","doi-asserted-by":"publisher","first-page":"111876","DOI":"10.1016\/j.jep.2019.111876","volume":"238","author":"A Saref","year":"2019","unstructured":"Saref A, Suraya S, Singh D, et al. Self-reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects. J Ethnopharmacol. 2019;238:111876.","journal-title":"J Ethnopharmacol"},{"key":"2142_CR24","doi-asserted-by":"publisher","first-page":"108426","DOI":"10.1016\/j.drugalcdep.2020.108426","volume":"218","author":"J Ahmad","year":"2021","unstructured":"Ahmad J, Odin JA, Hayashi PH, et al. Liver injury associated with kratom, a popular opioid-like product: experience from the US drug induced liver injury network and a review of the literature. Drug Alcohol Depend. 2021;218:108426.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"2142_CR25","first-page":"54","volume":"120","author":"C Stanciu","year":"2021","unstructured":"Stanciu C, Ahmed S, Hybki B, et al. Pharmacotherapy for management of \u2018kratom use disorder\u2019: a systematic literature review with survey of experts. WMJ. 2021;120(1):54\u201361.","journal-title":"WMJ"},{"key":"2142_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3389\/fpsyt.2017.00062","volume":"8","author":"D Fluyau","year":"2017","unstructured":"Fluyau D, Revadigar N. Biochemical benefits, diagnosis, and clinical risks evaluation of kratom. Front Psych. 2017;8:62.","journal-title":"Front Psych"},{"key":"2142_CR27","doi-asserted-by":"publisher","unstructured":"Wahbeh A, Nasralah T, El-Gayar O, et al. Adverse health effects of kratom: an analysis of social media data. 2021. https:\/\/doi.org\/10.24251\/HICSS.2021.477.","DOI":"10.24251\/HICSS.2021.477"},{"issue":"7","key":"2142_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/phar.2280","volume":"39","author":"W Eggleston","year":"2019","unstructured":"Eggleston W, Stoppacher R, Suen K, et al. Kratom use and toxicities in the United States. Pharmacotherapy. 2019;39(7):775\u20137.","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2142_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40265-019-01242-6","volume":"80","author":"J Schimmel","year":"2020","unstructured":"Schimmel J, Dart RC. Kratom (Mitragyna speciosa) liver injury: a comprehensive review. Drugs. 2020;80(3):263\u201383.","journal-title":"Drugs"},{"key":"2142_CR30","first-page":"117822182210958","volume":"16","author":"CW Striley","year":"2022","unstructured":"Striley CW, Hoeflich CC, Viegas AT, et al. Health effects associated with kratom (Mitragyna speciosa) and polysubstance use: a narrative review. Subst Abuse. 2022;16:11782218221095872.","journal-title":"Subst Abuse"},{"issue":"8","key":"2142_CR31","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1111\/jgs.17326","volume":"69","author":"JM Graves","year":"2021","unstructured":"Graves JM, Dilley JA, Terpak L, et al. Kratom exposures among older adults reported to US poison centers, 2014\u20132019. J Am Geriatr Soc. 2021;69(8):2176\u201384.","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"2142_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/15563650.2019.1569236","volume":"57","author":"S Post","year":"2019","unstructured":"Post S, Spiller HA, Chounthirath T, et al. Kratom exposures reported to United States poison control centers: 2011\u20132017. Clin Toxicol. 2019;57(10):847\u201354.","journal-title":"Clin Toxicol"},{"key":"2142_CR33","doi-asserted-by":"publisher","unstructured":"Ellis MS, Buttram ME, Forber A, et al. Associations between kratom-related state policy environments and kratom use in a nationally representative population in the United States. J Psychoactive Drugs. 2023:1\u20139. https:\/\/doi.org\/10.1080\/02791072.2023.2223622.","DOI":"10.1080\/02791072.2023.2223622"},{"key":"2142_CR34","unstructured":"Sprout Health Group. Is kratom legal? Kratom legality by state n.d. [Available from: https:\/\/www.sprouthealthgroup.com\/substances\/is-kratom-legal-by-state\/.\u00a0Accessed Oct 2023."},{"key":"2142_CR35","unstructured":"Legislative Analysis and Public Policy Association. Kratom: summary of state laws 2023 [Available from: https:\/\/legislativeanalysis.org\/kratom-summary-of-state-laws\/.\u00a0Accessed Oct 2023."},{"issue":"1","key":"2142_CR36","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.amepre.2018.07.032","volume":"56","author":"DT Duncan","year":"2019","unstructured":"Duncan DT, Zweig S, Hambrick HR, et al. Sexual orientation disparities in prescription opioid misuse among US adults. Am J Prev Med. 2019;56(1):17\u201326.","journal-title":"Am J Prev Med"},{"issue":"8","key":"2142_CR37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1089\/lgbt.2020.0220","volume":"7","author":"E Morgan","year":"2020","unstructured":"Morgan E, Feinstein BA, Dyar C. Disparities in prescription opioid misuse affecting sexual minority adults are attenuated by depression and suicidal ideation. LGBT Health. 2020;7(8):431\u20138.","journal-title":"LGBT Health"},{"key":"2142_CR38","doi-asserted-by":"publisher","first-page":"109605","DOI":"10.1016\/j.drugalcdep.2022.109605","volume":"239","author":"D Adzrago","year":"2022","unstructured":"Adzrago D, Obekpa EO, Suragh TA, et al. Kratom use categories and their associations with co-occurring substance use and mental health disorder symptoms during the COVID-19 pandemic. Drug Alcohol Depend. 2022;239:109605.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"2142_CR39","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/socpro\/spab027","volume":"68","author":"SL Lindsay","year":"2021","unstructured":"Lindsay SL, Vuolo M. Criminalized or medicalized? Examining the role of race in responses to drug use. Soc Probl. 2021;68(4):942\u201363.","journal-title":"Soc Probl"},{"key":"2142_CR40","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.drugalcdep.2012.05.005","volume":"125","author":"N Mulvaney-Day","year":"2012","unstructured":"Mulvaney-Day N, DeAngelo D, Chen C-n, et al. Unmet need for treatment for substance use disorders across race and ethnicity. Drug Alcohol Depend. 2012;125:S44\u201350.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"2142_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1080\/15332640.2017.1336959","volume":"17","author":"B Lewis","year":"2018","unstructured":"Lewis B, Hoffman L, Garcia CC, et al. Race and socioeconomic status in substance use progression and treatment entry. J Ethn Subst Abuse. 2018;17(2):150\u201366.","journal-title":"J Ethn Subst Abuse"},{"issue":"2","key":"2142_CR42","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/jamapsychiatry.2013.3575","volume":"71","author":"JR Cummings","year":"2014","unstructured":"Cummings JR, Wen H, Ko M, et al. Race\/ethnicity and geographic access to Medicaid substance use disorder treatment facilities in the United States. JAMA Psychiat. 2014;71(2):190\u20136.","journal-title":"JAMA Psychiat"},{"key":"2142_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12914-015-0072-9","volume":"16","author":"G Alencar Albuquerque","year":"2016","unstructured":"Alencar Albuquerque G, de Lima GC, da Silva QG, et al. Access to health services by lesbian, gay, bisexual, and transgender persons: systematic literature review. BMC Int Health Hum Rights. 2016;16:1\u201310.","journal-title":"BMC Int Health Hum Rights"},{"issue":"4","key":"2142_CR44","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1007\/s40615-022-01384-6","volume":"10","author":"MC Gondr\u00e9-Lewis","year":"2023","unstructured":"Gondr\u00e9-Lewis MC, Abijo T, Gondr\u00e9-Lewis TA. The opioid epidemic: a crisis disproportionately impacting Black Americans and urban communities. J Racial Ethn Health Disparities. 2023;10(4):2039\u201353.","journal-title":"J Racial Ethn Health Disparities"},{"issue":"2","key":"2142_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1177\/1073110518782949","volume":"46","author":"K James","year":"2018","unstructured":"James K, Jordan A. The opioid crisis in black communities. J Law Med Ethics. 2018;46(2):404\u201321.","journal-title":"J Law Med Ethics"},{"key":"2142_CR46","unstructured":"NSDUH. Population data and methods 2023 [Available from: https:\/\/www.datafiles.samhsa.gov\/dataset\/national-survey-drug-use-and-health-2020-nsduh-2020-ds0001.\u00a0Accessed Oct 2023."},{"key":"2142_CR47","unstructured":"NSDUH. Welcome to the National Survey on Drug Use and Health (NSDUH) 2021 [Available from: https:\/\/nsduhweb.rti.org\/respweb\/homepage.cfm.\u00a0Accessed Oct 2023."},{"issue":"1","key":"2142_CR48","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/02791072.2018.1562133","volume":"51","author":"CN Stanciu","year":"2019","unstructured":"Stanciu CN, Gnanasegaram SA, Ahmed S, et al. Kratom withdrawal: a systematic review with case series. J Psychoactive Drugs. 2019;51(1):12\u20138.","journal-title":"J Psychoactive Drugs"},{"issue":"5","key":"2142_CR49","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/10550490701525368","volume":"16","author":"EW Boyer","year":"2007","unstructured":"Boyer EW, Babu KM, Macalino GE, et al. Self-treatment of opioid withdrawal with a dietary supplement, kratom. Am J Addict. 2007;16(5):352\u20136.","journal-title":"Am J Addict"},{"issue":"3","key":"2142_CR50","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/acem.12328","volume":"21","author":"M Mazer-Amirshahi","year":"2014","unstructured":"Mazer-Amirshahi M, Mullins PM, Rasooly I, et al. Rising opioid prescribing in adult US emergency department visits: 2001\u20132010. Acad Emerg Med. 2014;21(3):236\u201343.","journal-title":"Acad Emerg Med"},{"key":"2142_CR51","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s40122-017-0080-7","volume":"6","author":"EE Shipton","year":"2017","unstructured":"Shipton EE, Shipton AJ, Williman JA, et al. Deaths from opioid overdosing: implications of coroners\u2019 inquest reports 2008\u20132012 and annual rise in opioid prescription rates: a population-based cohort study. Pain Ther. 2017;6:203\u201315.","journal-title":"Pain Ther"},{"issue":"15","key":"2142_CR52","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1001\/jama.2016.1910","volume":"315","author":"Y Olsen","year":"2016","unstructured":"Olsen Y. The CDC guideline on opioid prescribing: rising to the challenge. JAMA. 2016;315(15):1577\u20139.","journal-title":"JAMA"},{"issue":"1","key":"2142_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ajem.2018.09.052","volume":"37","author":"KL Boyle","year":"2019","unstructured":"Boyle KL, Cary C, Dizitzer Y, et al. Reduction of opioid prescribing through the sharing of individual physician opioid prescribing practices. Am J Emerg Med. 2019;37(1):118\u201322.","journal-title":"Am J Emerg Med"},{"issue":"3","key":"2142_CR54","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1097\/SLA.0000000000002198","volume":"267","author":"MV Hill","year":"2018","unstructured":"Hill MV, Stucke RS, McMahon ML, et al. An educational intervention decreases opioid prescribing after general surgical operations. Ann Surg. 2018;267(3):468\u201372.","journal-title":"Ann Surg"},{"key":"2142_CR55","doi-asserted-by":"publisher","unstructured":"Smith KE, Dunn KE, Rogers JM, et al. Kratom use as more than a \u201cself-treatment\u201d. Am J Drug Alcohol Abuse. 2022:1\u201311. https:\/\/doi.org\/10.1080\/00952990.2022.2083967.","DOI":"10.1080\/00952990.2022.2083967"},{"key":"2142_CR56","doi-asserted-by":"publisher","first-page":"107618","DOI":"10.1016\/j.drugalcdep.2019.107618","volume":"206","author":"MS Ellis","year":"2020","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. The impact of opioid use disorder on levels of educational attainment: perceived benefits and consequences. Drug Alcohol Depend. 2020;206:107618.","journal-title":"Drug Alcohol Depend"},{"key":"2142_CR57","doi-asserted-by":"crossref","unstructured":"Powell D (ed). Educational attainment and US drug overdose deaths. JAMA Health Forum. American Medical Association; 2023.","DOI":"10.1001\/jamahealthforum.2023.3274"},{"issue":"5","key":"2142_CR58","doi-asserted-by":"publisher","first-page":"e2709","DOI":"10.1002\/hup.2709","volume":"34","author":"JA Nicewonder","year":"2019","unstructured":"Nicewonder JA, Buros AF, Veltri CA, et al. Distinct kratom user populations across the United States: a regional analysis based on an online survey. Hum Psychopharmacol Clin Exp. 2019;34(5):e2709.","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"4","key":"2142_CR59","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/10550887.2020.1788914","volume":"38","author":"JR Covvey","year":"2020","unstructured":"Covvey JR, Vogel SM, Peckham AM, et al. Prevalence and characteristics of self-reported kratom use in a representative US general population sample. J Addict Dis. 2020;38(4):506\u201313.","journal-title":"J Addict Dis"},{"issue":"7","key":"2142_CR60","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11606-005-0105-5","volume":"20","author":"I Chen","year":"2005","unstructured":"Chen I, Kurz J, Pasanen M, et al. Racial differences in opioid use for chronic nonmalignant pain. J Gen Intern Med. 2005;20(7):593\u20138.","journal-title":"J Gen Intern Med"},{"key":"2142_CR61","doi-asserted-by":"publisher","unstructured":"Santoro TN, Santoro JD. Racial bias in the US opioid epidemic: a review of the history of systemic bias and implications for care. Cureus. 2018;10(12). https:\/\/doi.org\/10.7759\/cureus.3733.","DOI":"10.7759\/cureus.3733"},{"issue":"8","key":"2142_CR62","doi-asserted-by":"publisher","first-page":"941","DOI":"10.3109\/10826084.2013.776084","volume":"49","author":"DV Flores","year":"2014","unstructured":"Flores DV, Torres LR, Torres-Vigil I, et al. From \u201ckickeando las malias\u201d(kicking the withdrawals) to \u201cstaying clean\u201d: the impact of cultural values on cessation of injection drug use in aging Mexican-American men. Subst Use Misuse. 2014;49(8):941\u201354.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"2142_CR63","doi-asserted-by":"publisher","first-page":"e2582","DOI":"10.1002\/hup.2582","volume":"32","author":"D Singh","year":"2017","unstructured":"Singh D, Narayanan S, Vicknasingam B, et al. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol Clin Exp. 2017;32(3):e2582.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"2142_CR64","doi-asserted-by":"publisher","unstructured":"Cinosi E, Martinotti G, Simonato P, et al. Following \u201cthe roots\u201d of kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in western countries. BioMed Res Int. 2015;2015. https:\/\/doi.org\/10.1155\/2015\/968786.","DOI":"10.1155\/2015\/968786"},{"key":"2142_CR65","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s11013-016-9496-5","volume":"40","author":"J Netherland","year":"2016","unstructured":"Netherland J, Hansen HB. The war on drugs that wasn\u2019t: wasted whiteness, \u201cdirty doctors\u201d, and race in media coverage of prescription opioid misuse. Cult Med Psychiatry. 2016;40:664\u201386.","journal-title":"Cult Med Psychiatry"},{"issue":"5","key":"2142_CR66","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.addbeh.2009.12.019","volume":"35","author":"HL Corliss","year":"2010","unstructured":"Corliss HL, Rosario M, Wypij D, et al. Sexual orientation and drug use in a longitudinal cohort study of US adolescents. Addict Behav. 2010;35(5):517\u201321.","journal-title":"Addict Behav"},{"key":"2142_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.addbeh.2015.02.017","volume":"46","author":"ML Hatzenbuehler","year":"2015","unstructured":"Hatzenbuehler ML, Jun H-J, Corliss HL, et al. Structural stigma and sexual orientation disparities in adolescent drug use. Addict Behav. 2015;46:14\u20138.","journal-title":"Addict Behav"},{"issue":"2","key":"2142_CR68","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2105\/AJPH.2013.301702","volume":"104","author":"ME Newcomb","year":"2014","unstructured":"Newcomb ME, Birkett M, Corliss HL, et al. Sexual orientation, gender, and racial differences in illicit drug use in a sample of US high school students. Am J Public Health. 2014;104(2):304\u201310.","journal-title":"Am J Public Health"},{"issue":"4","key":"2142_CR69","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1360-0443.2008.02149.x","volume":"103","author":"MP Marshal","year":"2008","unstructured":"Marshal MP, Friedman MS, Stall R, et al. Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction. 2008;103(4):546\u201356.","journal-title":"Addiction"},{"key":"2142_CR70","doi-asserted-by":"publisher","unstructured":"Williams R, Romm KF, LoParco CR, et al. Experiences of microaggressions, attributions, and impact among US young adults: an intersectional perspective regarding sexual\/gender and racial\/ethnic minorities. J Racial Ethn Health Disparities. 2023:1\u201315. https:\/\/doi.org\/10.1007\/s40615-023-01710-6.","DOI":"10.1007\/s40615-023-01710-6"}],"container-title":["Journal of Racial and Ethnic Health Disparities"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-024-02142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40615-024-02142-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40615-024-02142-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:12:05Z","timestamp":1758208325000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40615-024-02142-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":70,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2142"],"URL":"https:\/\/doi.org\/10.1007\/s40615-024-02142-6","relation":{},"ISSN":["2197-3792","2196-8837"],"issn-type":[{"value":"2197-3792","type":"print"},{"value":"2196-8837","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These data were determined to be not human subjects data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Data are publicly available; all participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors have read and agreed to the published version of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}